GRI Bio, Inc. SEC filings GRI
GRI Bio, Inc. has 402 filings in SEC EDGAR's recent list, going back to Sep 11, 2020. Its latest annual report, Form ARS, was filed on Sep 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (officer or director change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jan 30, 2026 | — |
| CORRESP | Letter to the SEC | Jan 30, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2026 | — |
| EFFECT | Filing | Dec 11, 2025 | — |
| CORRESP | Letter to the SEC | Dec 9, 2025 | — |
| CORRESP | Letter to the SEC | Dec 9, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2025 | — |
| DRSLTR | Filing | Aug 15, 2025 | — |
| DRS | Filing | Aug 15, 2025 | — |
| EFFECT | Filing | Apr 1, 2025 | — |
| CORRESP | Letter to the SEC | Mar 26, 2025 | — |
| CORRESP | Letter to the SEC | Mar 26, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2025 | — |
| DRS | Filing | Mar 14, 2025 | — |
| EFFECT | Filing | Nov 22, 2024 | — |
| CORRESP | Letter to the SEC | Nov 20, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2024 | — |
| D | Filing | Oct 25, 2024 | — |
| EFFECT | Filing | Jun 26, 2024 | — |
| CORRESP | Letter to the SEC | Jun 25, 2024 | — |
| CORRESP | Letter to the SEC | Jun 25, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2024 | — |
| EFFECT | Filing | May 16, 2024 | — |
| CORRESP | Letter to the SEC | May 14, 2024 | — |
| UPLOAD | Letter from the SEC | May 14, 2024 | — |
| EFFECT | Filing | Feb 1, 2024 | — |
| CORRESP | Letter to the SEC | Jan 30, 2024 | — |
| CORRESP | Letter to the SEC | Jan 30, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 26, 2023 | — |
| EFFECT | Filing | Dec 15, 2023 | — |
| CORRESP | Letter to the SEC | Dec 14, 2023 | — |
| CORRESP | Letter to the SEC | Dec 4, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2023 | — |
| EFFECT | Filing | Jun 7, 2023 | — |
| CORRESP | Letter to the SEC | Jun 5, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 5, 2023 | — |
| D | Filing | Apr 27, 2023 | — |
| 425 | Filing | Apr 12, 2023 | — |
| 425 | Filing | Apr 7, 2023 | — |
| 425 | Filing | Apr 4, 2023 | — |
| EFFECT | Filing | Mar 8, 2023 | — |
| CORRESP | Letter to the SEC | Mar 6, 2023 | — |
| CORRESP | Letter to the SEC | Feb 24, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 14, 2023 | — |
| CORRESP | Letter to the SEC | Feb 9, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2023 | — |
| CORRESP | Letter to the SEC | Jan 27, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2023 | — |
| 425 | Filing | Jan 11, 2023 | — |
| EFFECT | Filing | Jun 8, 2022 | — |
| CORRESP | Letter to the SEC | Jun 6, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2022 | — |
| EFFECT | Filing | May 2, 2022 | — |
| CORRESP | Letter to the SEC | Apr 28, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 28, 2022 | — |
| SEC STAFF LETTER | Filing | Feb 10, 2021 | — |
| EFFECT | Filing | Feb 9, 2021 | — |
| CERT | 8a cert | Feb 9, 2021 | — |
| 8-A12B | Filing | Feb 8, 2021 | — |
| CORRESP | Letter to the SEC | Feb 3, 2021 | — |
| CORRESP | Letter to the SEC | Feb 3, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| CORRESP | Letter to the SEC | Feb 1, 2021 | — |
| CORRESP | Letter to the SEC | Feb 1, 2021 | — |
| CORRESP | Letter to the SEC | Jan 28, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 22, 2021 | — |
| SEC STAFF LETTER | Filing | Nov 17, 2020 | — |
| CORRESP | Letter to the SEC | Nov 16, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 6, 2020 | — |
| CORRESP | Letter to the SEC | Oct 23, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 9, 2020 | — |
| DRS | Filing | Sep 11, 2020 | — |
Showing 72 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GRI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1824293
- Former names
- Vallon Pharmaceuticals, Inc. (until Apr 21, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.